These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8282507)

  • 1. Low-osmolality contrast media and the risk of contrast-associated nephrotoxicity.
    Goldfarb S; Spinler S; Berns JS; Rudnick MR
    Invest Radiol; 1993 Nov; 28 Suppl 5():S7-10; discussion S11-2. PubMed ID: 8282507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Briguori C; Colombo A; Airoldi F; Morici N; Sangiorgi GM; Violante A; Focaccio A; Montorfano M; Carlino M; Condorelli G; Ricciardelli B
    Kidney Int; 2005 Nov; 68(5):2250-5. PubMed ID: 16221226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast media: are there differences in nephrotoxicity among contrast media?
    Solomon R
    Biomed Res Int; 2014; 2014():934947. PubMed ID: 24587997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of low-osmolar and iso-osmolar contrast media.
    Heinrich M; Uder M
    Kidney Int; 2006 Mar; 69(6):1095. PubMed ID: 16528264
    [No Abstract]   [Full Text] [Related]  

  • 5. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial.
    Moore RD; Steinberg EP; Powe NR; Brinker JA; Fishman EK; Graziano S; Gopalan R
    Radiology; 1992 Mar; 182(3):649-55. PubMed ID: 1535876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
    Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
    Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of contrast media following cardiac angiography: pathogenesis, clinical course, and preventive measures, including the role of low-osmolality contrast media.
    Spinler SA; Goldfarb S
    Ann Pharmacother; 1992 Jan; 26(1):56-64. PubMed ID: 1606346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-osmolality versus high-osmolality contrast material.
    Korn WT; Bettmann MA
    Curr Opin Radiol; 1992 Apr; 4(2):9-15. PubMed ID: 1554592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of low osmolality contrast media versus high osmolality media.
    Steinberg EP; Moore RD; Brinker JA; Fishman EK; Powe NR; Graziano SL; Gopalan R
    Invest Radiol; 1991 Nov; 26 Suppl 1():S86; discussion S88-91. PubMed ID: 1808157
    [No Abstract]   [Full Text] [Related]  

  • 10. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
    Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast media-associated nephrotoxicity.
    Rudnick MR; Berns JS; Cohen RM; Goldfarb S
    Semin Nephrol; 1997 Jan; 17(1):15-26. PubMed ID: 9000546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis.
    Biondi-Zoccai G; Lotrionte M; Thomsen HS; Romagnoli E; D'Ascenzo F; Giordano A; Frati G
    Int J Cardiol; 2014 Mar; 172(2):375-80. PubMed ID: 24502883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review.
    Rudnick MR; Berns JS; Cohen RM; Goldfarb S
    Am J Kidney Dis; 1994 Oct; 24(4):713-27. PubMed ID: 7942832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media.
    Barrett BJ; Carlisle EJ
    Radiology; 1993 Jul; 188(1):171-8. PubMed ID: 8511292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. For patients with renal insufficiency, do low-osmolar iodinated contrast agents lessen the risk of nephrotoxicity, compared with high-osmolar agents?
    Hopper KD
    AJR Am J Roentgenol; 1997 Jun; 168(6):1615. PubMed ID: 9168738
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
    Rudnick MR; Davidson C; Laskey W; Stafford JL; Sherwin PF;
    Am Heart J; 2008 Oct; 156(4):776-82. PubMed ID: 18946896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The osmolality of nonionic, iodinated contrast agents as an important factor for renal safety.
    Lenhard DC; Pietsch H; Sieber MA; Ernst R; Lengsfeld P; Ellinghaus P; Jost G
    Invest Radiol; 2012 Sep; 47(9):503-10. PubMed ID: 22864374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxic effects in high-risk patients undergoing angiography.
    Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
    N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent clinical trials of iodixanol.
    Erdogan A; Davidson CJ
    Rev Cardiovasc Med; 2003; 4 Suppl 5():S43-50. PubMed ID: 14668709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.